Cardiovascular disease is an important burden in the Western world, with a prevalence that is increasing exponentially. Indeed, the lifetime risk of coronary artery disease at 40 years of age is 1 in 2 for men and 1 in 3 for women, and it is estimated that one-third of the population worldwide will die of cardiovascular disease, with a majority of these deaths related to MI (myocardial infarction) or the complications of MI. Recent research has suggested that EPO (erythropoietin), an endogenous erythropoietic hormone, may have pleiotropic effects well beyond the maintenance of red blood cells, and may have a cardiovascular role as well, including a potentially salutary effect on reperfusion injury. Although findings supportive of a role of EPO as a cardioprotective agent appear promising, the mechanisms behind the observed benefits remain elusive. In the present issue of Clinical Science, Piuhola and co-workers provide an interesting study that may shed light on the effects of EPO (and possibly related compounds) in the context of acute MI.
Skip Nav Destination
Commentary| January 15 2008
Erythropoietin in cardiovascular diseases: exploring new avenues
Peter van der Meer;
*Cardiology Division, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, U.S.A.
†Department of Cardiology, University Medical Center Groningen, 9700 RB Groningen, The Netherlands
Correspondence: Dr Peter van der Meer (email email@example.com).
Search for other works by this author on:
Dirk J. van Veldhuisen;
- Views Icon Views
- Share Icon Share
Peter van der Meer, Dirk J. van Veldhuisen, James L. Januzzi; Erythropoietin in cardiovascular diseases: exploring new avenues. Clin Sci (Lond) 1 February 2008; 114 (4): 289–291. doi: https://doi.org/10.1042/CS20070392
Download citation file:
Don't already have an account? Register
Get Access To This Article
Buy This Article